keyboard_arrow_up

Single Use Bioreactor Market (Recombinant Proteins, Monoclonal Antibodies) worth $470.9 Million by 2019

The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014. Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market.

The global Single Use Bioreactor Market is poised to reach $470.9 Million by 2019 from $202.5 Million in 2014, at a CAGR of 18.4% from 2014 to 2019.

Factors such as low operational costs, lesser requirement of monitoring and maintenance than traditional bioreactors, ease in culturing of marine microorganism such as algae, and low energy consumption are the factors driving the growth of the SUB market. In addition, the tremendous growth potential of the biologics market is offering robust growth opportunities to market players. However, low volume capacity and lack of availability of sterilized sensors are hindering the growth of this market.

The SUB market is segmented on the basis of molecule type, type of cell, technology, end user, and region. Based on molecule type, the SUB market is segmented into monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference). MAbs accounted for the majority of the global SUB market in 2014.

For Further Inquiry: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=49113750

On the basis of type of cell, the SUB market is broadly classified into mammalian cells, bacterial cells, yeast cells and others (insect cells and plant cells). Mammalian cells are the largest and fastest-growing segment of the SUB market. The large share of this market can be attributed to the higher efficacy of biomolecules expressed by mammalian cells.

The technology segment is categorized into the wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors). The wave-induced motion SUB segment accounted for the largest share and is estimated to grow at the fastest rate in the forecast period.

Based on end users, the Single Use Bioreactor Market is segmented into R&D department (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers. The R&D end-user segment accounted for the major market share in 2014. The biopharmaceutical manufacturers segment, on the other hand will witness the highest growth rate.

Speak to Research Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=49113750

On the basis of region, the SUB market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2014, Europe is expected to account for the largest share of the SUB market, followed by North America. Both markets are estimated to register double-digit growth rates over the next five years. However, Asia-Pacific is expected to register a higher growth rate during the forecast period, owing to huge investment opportunities available to biologics manufacturers in this region. Growth of the SUB market in the Asia-Pacific region will revolve around China, India, Australia, South Korea, Taiwan and countries in the Middle East.

Major players operating in the Single Use Bioreactor Market are Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.).

 About MarketsandMarkets

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. 

Contact:
Mr. Rohan
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology